The making of DNA

Enabling the genetic medicine revolution with our unique doggybone DNA (dbDNA™) technology.

How we make DNA
Platform Technology

doggybone DNA:
Powering the genetic medicine revolution

Our novel, synthetic DNA vector, doggybone DNA or dbDNA™, and its enzymatic production, enable us to make DNA at the speed, scale and purity necessary to support the rapid growth of genetic medicines.

Doggybone DNA animation
Enzymatic DNA

DNA made using enzymes

We are disrupting the decades-old technology of DNA production, moving away from restrictive biological approaches to instead use a synthetic DNA vector.

Our platform technology
Rapid enzymatic DNA technology
Rapid

Enzymatic manufacturing enables multi-gram GMP DNA production in weeks rather than months

Scalable enzymatic DNA technology
Scalable

Manufactured using benchtop equipment with a significantly smaller footprint than fermentation-based production

Mobile enzymatic DNA
Mobile

doggybone DNA technology is highly portable and amenable to technology transfer

Optimal enzymatic DNA vector
Optimal vector

doggybone DNA can encode long, complex, unstable sequences, eliminates bacterial sequences, and has a strong expression profile

Addressing a broad market

Our versatile doggybone DNA (dbDNA) technology is being applied across the genetic medicine industry.

mRNA icon

mRNA

Find out more
Lentivirus

Lentivirus

Find out more
AAV icon

AAV

Find out more
Genome editing icon

Genome editing

Find out more
DNA vaccines icon

DNA vaccines

Find out more
Non viral gene therapy

Non-viral gene therapy

Find out more
Our Services

What can we do for you?

We offer a range of services to support development and commercialisation of the next generation of DNA products.

doggybone DNA for pre-clinical development
Pre-clinical services
  • Catalogue products
  • Molecular biology
  • Custom research grade
  • Toxicology materials
Find out more
enzymatic doggybone DNA GMP Supply
GMP supply
  • GMP dbDNA™ (critical starting materials)
  • GMP dbDNA™ (drug substance)
  • Commercial supply / on-site supply
Find out more
enzymatic DNA development services
Development Services
  • Analytical development
  • Scale up development
  • Formulation
  • Stability
Find out more
Regulatory Support for genetic medicine development
Regulatory support
  • Regulatory support
Find out more
Our facilities

Headquartered in Hampton

Take a tour of our stunning buildings and state-of-the-art DNA manufacturing facilities.

View our facilities
Our programs and partners

Work with us to develop the next generation of DNA products

We are working in collaboration with esteemed partners, to leverage doggybone DNA in areas where it may offer unique or improved therapies or devices.

Find out more
Find out more

Knowledge Centre

Article – Rewriting the Rules of Gene Therapy with Nonviral DNA Delivery
Read Article
Article – MegaBulb DNA: A Non-Viral ssDNA Breakthrough Revolutionising Gene Editing
Read Article
Article – Revolutionising the Genetic Medicine Landscape with Enzymatic DNA
Read Article
Article – Transforming the Economics of AAV Production whilst Optimising Quality Using dbDNA™
Read Article
Webinar – Non-viral Cell Engineering with Stanford University, Touchlight, and MaxCyte: Advantages and Applications
Read Article
Touchlight webinar December 2023
Webinar – Optimizing Personalized Cancer Immunotherapy Manufacturing Using Enzymatic DNA
Read Article
Knowledge centre

News

21 August 2024

Touchlight to supply GMP dbDNA to support University of Nottingham’s clinical study for a next-generation vaccine for Zika virus

Touchlight, an innovation-driven contract development and manufacturing organization (CDMO) specializing in enzymatic DNA production, is proud to announce the clinical supply of its proprietary dbDNATM to the University of Nottingham...

23 July 2024

Touchlight and GSK sign license agreement for use of enzymatic dbDNA production technology for mRNA manufacturing

Agreement enables GSK access to enzymatic production technology for rapid GMP production of DNA template for mRNA vaccine manufacturing Hampton, UK, 23 July 2024 – Touchlight, an innovation-driven CDMO pioneering...

02 July 2024

Touchlight and LenioBio collaborate to accelerate development of protein therapeutics for pandemic response

Touchlight to participate in LenioBio’s recently announced grant from CEPI 02 July, HAMPTON, United Kingdon and DÜSSELDORF, Germany - LenioBio, a biotech company pioneering cell-free protein production, and Touchlight, the...
All news
Contact us

We'd like to hear from you

For more information on how our doggybone DNA technology could help advance your project, please contact us.

Get in touch